Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) was upgraded by research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report released on Monday.
Separately, Maxim Group initiated coverage on Interpace Diagnostics Group in a research note on Tuesday, August 15th. They set a “buy” rating and a $5.00 price objective for the company.
Interpace Diagnostics Group (IDXG) opened at 1.60 on Monday. The company’s market capitalization is $35.46 million. Interpace Diagnostics Group has a 52 week low of $0.07 and a 52 week high of $14.25. The company’s 50-day moving average price is $1.17 and its 200-day moving average price is $1.76.
Interpace Diagnostics Group (NASDAQ:IDXG) last posted its quarterly earnings data on Thursday, August 10th. The business services provider reported ($0.65) EPS for the quarter. Interpace Diagnostics Group had a negative return on equity of 32.06% and a negative net margin of 37.08%. The firm had revenue of $3.86 million for the quarter.
A hedge fund recently bought a new stake in Interpace Diagnostics Group stock. Susquehanna International Group LLP purchased a new stake in Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 718,076 shares of the business services provider’s stock, valued at approximately $646,000. Susquehanna International Group LLP owned approximately 3.84% of Interpace Diagnostics Group at the end of the most recent reporting period. 7.58% of the stock is owned by institutional investors and hedge funds.
About Interpace Diagnostics Group
Interpace Diagnostics Group, Inc, formerly PDI, Inc, is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management.
Receive News & Ratings for Interpace Diagnostics Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group Inc. and related companies with MarketBeat.com's FREE daily email newsletter.